Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma
NCT04939272Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jun 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib and venetoclax in mantle cell lymphoma (MCL), sponsored by City of Hope. Primary endpoints: Incidence of dose limiting toxicities and Overall response rate up to 2 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
copanlisibvenetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04939272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939272.